Wednesday, April 30th, 2025

Oiltek : target price is set at $1.33 (8% upside), with a subsequent goal of $1.60 (30% upside), both of which are expected to be achieved.

Oiltek International has announced record earnings of RM29.6 million for FY2024, marking a 55% increase. Revenue also reached a record high of RM230.3 million, reflecting a 14.5% rise from FY2023.

The company’s strong performance is primarily driven by its core business of constructing refineries for both edible and non-edible oil sectors.

In FY2024, Oiltek secured RM207 million in new orders, bringing its total order book to RM354.9 million. As of December 31, 2024, the company maintains a healthy cash balance of RM106.1 million with zero debt.

Oiltek has proposed a final dividend of 1.8 cents, bringing its total full-year payout to 2.7 cents. This represents a payout ratio of 44.4% and a more than two-thirds increase compared to FY2023.

Looking ahead, Executive Director and CEO Henry Yong Khai Weng expressed confidence in the company’s growth prospects:
“As we enter the new financial year, we remain optimistic about our business and committed to driving growth while delivering long-term, sustainable value for our shareholders.”

The target price is set at $1.33 (8% upside), with a subsequent goal of $1.60 (30% upside), both of which are expected to be achieved.

Thank you

Yinson Holdings Bhd: Navigating Challenges and Driving Growth in the Energy Sector

Date: 01 October 2024Broker: UOB Kay Hian Private Limited Company Overview Yinson Holdings Bhd is one of the largest pure global Floating, Production, Storage and Offloading (FPSO) operators, with Engineering, Construction, Procurement, Installation and...

“Singapore Stock Market Update: NetLink Trust’s Stable Revenue and Key Market Insights”

Comprehensive Analysis of Listed Companies – Lim & Tan Securities (February 11, 2025) Comprehensive Analysis of Listed Companies – Lim & Tan Securities Report Date: February 11, 2025 Overview of Market Indices The FSSTI...

China Shineway Pharmaceutical Group Limited – 2024 Results Disappoint, Targets 10% Revenue Growth in 2025

China Shineway Pharmaceutical Faces Challenges, Eyes 10% Revenue Growth in 2025 UOB Kay Hian | March 31, 2025 China Shineway Pharmaceutical Group Limited (2877 HK) reported its 2024 results, which missed expectations, with revenue...